Weight Management · GLP-1 Medications

As of October 2026, no FDA-approved tirzepatide pill exists. Tirzepatide is approved only as a once-weekly injection, sold as Mounjaro and Zepbound. Two oral GLP-1 medications are now approved for weight management, the Wegovy pill and Foundayo, but neither one contains tirzepatide.

That answer surprises a lot of people, because searches for "tirzepatide in pill form" turn up plenty of products that look like exactly that. The gap between what's FDA-approved and what's advertised is the whole story here, so it's worth walking through what actually exists, how the approved pills compare with the injection, and what to ask before choosing any oral option.

Figures come from separate placebo-controlled trials with different populations and durations, so they show general ranges rather than a head-to-head ranking. (1,2,3)

Why Tirzepatide Is Still an Injection

Tirzepatide is a peptide, a chain of amino acids. It's the same basic kind of molecule as the proteins in your food, and your digestive system treats it that way. Stomach acid and digestive enzymes break peptides apart, and the few intact molecules that survive are too large to pass easily through the gut wall into the bloodstream. An injection avoids the problem entirely, which is a big part of why tirzepatide's weekly shot produces the results it does. That track record is covered in more depth in how tirzepatide compares with other GLP-1 medications.

Turning a peptide into a pill is possible, but it takes deliberate engineering. Oral semaglutide is the clearest example. It's paired with an absorption enhancer called SNAC, which briefly shields the drug from stomach acid and helps it cross the stomach lining. (4) Even then, only a small share of each dose reaches the bloodstream. That's why the Wegovy pill uses 25 mg a day, while the weekly Wegovy injection tops out at 2.4 mg. It's also why the pill comes with strict instructions about water and timing.

No equivalent formulation of tirzepatide has completed clinical trials or reached FDA review, and as of early 2026, industry pipeline trackers listed no oral tirzepatide in late-stage development by a major pharmaceutical company. (5) Eli Lilly, the company that makes tirzepatide, built its oral program around a completely different molecule.

The Two Oral GLP-1 Pills Approved for Weight Loss

The first, the Wegovy pill, was approved on December 22, 2025, as a once-daily 25 mg tablet of oral semaglutide. (6) In the OASIS 4 trial, adults who took it lost an average of about 16.6% of their body weight over 64 weeks, and roughly one in three lost 20% or more. (2) The trade-off is routine. You take it first thing in the morning on an empty stomach with no more than 4 ounces of plain water, then wait 30 minutes before eating, drinking anything else, or taking other oral medications. (7)

The second, Foundayo (orforglipron), was approved on April 1, 2026. (8) It works on the same GLP-1 receptor, but it isn't a peptide at all. Orforglipron is a small-molecule drug, closer in structure to a conventional pill, so it survives digestion without special shielding. That's why you can take Foundayo at any time of day, with or without food. In the ATTAIN-1 trial, participants on the highest dose lost an average of 11.2% to 12.4% of their body weight over 72 weeks, depending on how the analysis handled people who stopped treatment, compared with roughly 1–2% on placebo. (3) The commercial tablets are labeled differently than the trial doses. They range from 0.8 mg to 17.2 mg, with 17.2 mg corresponding to the highest dose studied. (8,9)

Neither pill has matched tirzepatide injections on average weight loss in its own trial, and that's the fair way to frame the choice. Pills trade some efficacy for convenience. For someone who has put off treatment because of needles, that may be a reasonable trade. For someone whose goal depends on the largest possible effect, the injection still has the stronger evidence behind it. The broader case for this class of medication is laid out in an argument for GLP-1 agonists.

What 'Tirzepatide in Pill Form' Usually Refers To

When you see tirzepatide sold as a tablet, sublingual tablet, drop, or gum, you're looking at a compounded product. A pharmacy has prepared it from tirzepatide ingredients, and it isn't a version of Mounjaro or Zepbound. Compounding has legitimate uses, but compounded drugs go to market without FDA review. The agency states plainly that it "does not review compounded drugs for safety, effectiveness or quality before they are marketed." (10)

The bigger question for oral and sublingual forms is evidence. The weight-loss results people associate with tirzepatide come from trials of the weekly injection. As of this writing, no large randomized controlled trial has shown that tirzepatide taken by mouth, under the tongue, or as gum produces comparable results. Given how much engineering it took to make oral semaglutide work, that isn't a detail to gloss over. It doesn't prove these products can't work. It means the evidence that they do hasn't been established the way it has for the injection.

Safety tracking points the same way. As of May 31, 2026, the FDA had received more than 730 adverse event reports involving compounded tirzepatide, including dosing errors, and it has asked prescribers to be vigilant. (10) If you're weighing any oral tirzepatide product, these questions are worth bringing to the prescriber:

Choosing Between a Pill and an Injection

Once the options are clear, the decision mostly comes down to five things: how much weight loss you're aiming for, how well a daily routine fits your life, what side effects you can tolerate, ease of usage, and what you'll actually pay. None of these has a universal right answer, and that's the point of working through it with a clinician rather than picking whichever format sounds easiest.

Side effects deserve a closer look, because a pill doesn't spare you from them. In ATTAIN-1, about a third of people on Foundayo's highest dose reported nausea, and about one in ten stopped treatment because of side effects, compared with under 3% on placebo. (3) That's the same pattern seen with injectable GLP-1s, and it's why every one of these medications starts low and increases gradually. Choosing a pill changes how you take the medication. It doesn't change what the medication does in your body.

Frequently Asked Questions About Oral Tirzepatide

This article is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Talk with a qualified healthcare provider before starting, stopping, or changing any medication.